Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | PEPD | P12955 | 1/20 | 0.33 |
| ▸ | GABRR1 | P24046 | 4/20 | 0.32 |
| ▸ | GABRR2 | P28476 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20919668 | 1.00 | TOP2A (0.35) | TOP2ATP53CYP3A4FKBP1AHTT | |
| SCHEMBL23389527 | 0.85 | GABRR1 (0.46) | TOP2AGABRR1GABRR2 | |
| SCHEMBL7296965 | 0.77 | PABPC1 (0.33) | FKBP1A | |
| SCHEMBL7291318 | 0.77 | PABPC1 (0.33) | FKBP1A | |
| SCHEMBL6099554 | 0.77 | CA1 (0.42) | FKBP1A | |
| SCHEMBL31153812 | 0.77 | RECQL (0.40) | SMN1; SMN2 | |
| SCHEMBL19884450 | 0.77 | CYP2C19 (0.40) | TP53CYP3A4HTTCYP2C19PEPD | |
| SCHEMBL16407750 | 0.76 | FKBP1A (0.44) | FKBP1A | |
| SCHEMBL7303649 | 0.75 | TOP2A (0.31) | TOP2A | |
| SCHEMBL7344040 | 0.75 | TOP2A (0.31) | TOP2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9770439-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-26 | — | — | US | disclosed |
| US-20160158200-A1 | Combinations of Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2016-06-09 | — | — | US | disclosed |
| US-20150297568-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2015-10-22 | — | — | US | disclosed |
| US-20150023913-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2015-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150023913-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, EIF2AK2 | TOP2A 2656/4885TP53 53/4885CYP3A4 2495/4885 |
| US-20150297568-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, EIF2AK2 | TOP2A 2656/4885TP53 53/4885CYP3A4 2495/4885 |
| US-20160158200-A1 | Combinations of Hepatitis C Virus Inhibitors | HAVCR2, EIF2AK2, MAVS | TOP2A 2458/4885TP53 42/4885CYP3A4 3019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.